

U.S.S.N.: 09/715,965  
Filed: November 17, 2000  
AMENDMENT

### Claims Listing

1. (Currently amended) A method to decrease angiogenesis comprising administering to a site in an individual in need of treatment thereof for an established disorder requiring angiogenesis an effective amount of a purified chondroitinase enzyme to decrease angiogenesis at the site, wherein the decrease in angiogenesis is measured as a decrease in endothelial cell proliferation or a decrease in the formation of capillary-like structures.
2. (Previously presented) The method of claim 1 wherein the enzyme is selected from the group consisting of chondroitinase AC from *Flavobacterium heparinum*, chondroitinase B from *Flavobacterium heparinum*, a chondroitin sulfate degrading enzyme from *Bacteroides* species, a chondroitin sulfate degrading enzyme from *Proteus vulgaris*, a chondroitin sulfate degrading enzyme from *Micrococcus*, a chondroitin sulfate degrading enzyme from *Vibrio* species, a chondroitin sulfate degrading enzyme from *Arthrobacter aureus*, and combinations thereof wherein these enzymes are expressed from recombinant nucleotide sequences in bacteria.
3. (Original) The method of claim 1 wherein the enzyme is a mammalian enzyme.
4. (Previously presented) The method of claim 8 wherein the enzyme is a chondroitinase AC.
5. (Previously presented) The method of claim 1 wherein the chondroitinase is chondroitinase AC.
6. (Previously presented) The method of claim 1 wherein the enzyme is administered to an individual having cancer as evidenced by palpable tumors.

U.S.S.N.: 09/715,965  
Filed: November 17, 2000  
**AMENDMENT**

7. (Original) The method of claim 6 wherein the cancer is a solid tumor and the enzyme is chondroitinase AC.

8. (Previously presented) The method of claim 1 wherein the individual has a disorder in which angiogenesis is involved, the disorder being selected from the group consisting of rheumatoid arthritis; psoriasis; ocular angiogenic disease, rubeosis; Osler-Webber Syndrome; myocardial angiogenesis; plaque neovascularization; telangiectasia; hemophiliac joints; angiofibroma; Crohn's disease, atherosclerosis, scleroderma, hypertrophic scarring, adhesions, cirrhosis of the liver, pulmonary fibrosis following acute respiratory distress syndrom or other pulmonary fibrosis of the newborn, endometriosis, polyposis, obesity, uterine fibroids, prostatic hypertrophy, and amyloidosis.

9. (Original) The method of claim 1 wherein the enzyme is administered systemically.

10. (Previously presented) The method of claim 1 wherein the enzyme is administered locally at or adjacent a site in need of treatment.

11. (Original) The method of claim 1 wherein the enzyme is administered in a controlled and/or sustained release formulation.

12. to 18. (canceled)

19. (Currently amended) The method of claim 7 wherein the chondroitinase is administered in a dosage [[is]] in the range of 0.1 to 250 IU chondroitinase AC/tumor for tumors in the size range from 20 mm<sup>3</sup> to 15 cm<sup>3</sup>.

U.S.S.N.: 09/715,965  
Filed: November 17, 2000  
AMENDMENT

20. (Original) The method of claim 1 wherein the enzyme is administered in combination with another active agent selected from the group consisting of antibiotics, cytokines, cytotoxic agents, and anti-inflammatories.

21. (Original) The method of claim 7 wherein the enzyme is administered after excision of the tumor.

22. (Original) The method of claim 9 wherein the enzyme is administered by a route selected from the group consisting of intravenous, intra-cranial, and depo.

23. (Original) The method of claim 9 wherein the enzyme is administered using an infusion pump.

24. (Original) The method of claim 1 wherein the enzyme is chondroitinase B.

25. (Original) The method of claim 8 wherein the enzyme is chondroitinase B.

26. (Original) The method of claim 1 wherein the individual has a disorder in which angiogenesis is involved, the disorder being selected from the group consisting of disease of excessive or abnormal stimulation of endothelial cells, diseases that have angiogenesis as a pathologic consequence, and scarring following transplantation.

27. (Original) The method of claim 1 wherein the enzyme is administered topically.